BHVN Stock Builds Momentum Ahead Of Multiple H2 2026 Clinical Data Readouts
The company is expected to announce clinical data for hard-to-treat epilepsy and obesity later this year.
Read the full articleStocktwits Inc2d ago
You might also wanna read
to the point: Healthcare & Life Sciences Q2/2026
......
Lexology·9d ago
Reuters Digital Health 2026: The End of the Single Decision-Maker in Healthcare Sales
Sometimes you only need a morning to get a read on a room.I dropped into the Reuters Digital Health 2026 event in Chicago for just a half-da
healthcareittoday.com·25d ago
Neurogene Completes Dosing in Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome; Topline Data Expected 2H 2027
Trial success hinges on 8 of 24 participants meeting Neurogene’s composite endpoint. Dosing is complete; topline Rett gene therapy data expe
stocktitan.net·1mo agoHims & Hers Health vs. Teladoc Health: Which Healthcare Stock Is a Better Buy in 2026?
One prioritizes rapid consumer growth and profitability; the other commands scale but faces concentration risk.
Bars·4d ago
Endevica spinout Kalohexis submits confidential IPO filing to develop obesity challenger to GLP-1s
Clinical-stage Kalohexis is readying a public listing to support its obesity and cancer cachexia treatments.
Fierce Biotech·3d ago
STAT+: Roche ends Huntington’s gene-silencing programs
ARPA-H launches bespoke gene therapy push, Lilly and Novo to promote Bridge program, and more biotech news from The Readout
STAT·20h ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.